Surgalign & NuVasive: How they line up in Q1

Medical technology companies Surgalign and NuVasive posted their first quarter financial results for 2023. 

Advertisement

Here is how they compare: 

Surgalign

Revenue: $16.7 million

Operating loss: $1.1 million 

Year-over-year revenue dip: $3.9 million

NuVasive

Sales: $307.7 million

Operating loss: $1 million

Year-over-year sales increase: $17 million

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.